Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
Orsolini et al.·Medicina (Kaunas, Lithuania)Impact 3.0
UnklarGRADEHoch136 Zitate
StichprobeSystematische Review
Dauerbis Mai 2019
EndpunktPTSD-Symptomatik
Verblindungunklar
DesignSystematic Review
”Kernaussage
Cannabis und synthetische Cannabinoide zeigen potenziellen therapeutischen Nutzen zur Verbesserung von PTSD-Symptomen, aber die aktuelle Evidenz bezüglich Sicherheit und Wirksamkeit ist begrenzt.
Zusammenfassung
Systematische Review zu medizinischem Cannabis und synthetischen Cannabinoiden bei PTBS (PRISMA-konform, PubMed/Cochrane/Web of Science bis Mai 2019). Cannabis und synthetische Cannabinoide zeigen therapeutisches Potenzial zur Verbesserung von PTBS-Symptomen (Angstreduktion, Modulation gedächtnisassoziierter Prozesse, Schlafverbesserung) durch Wirkung am Endocannabinoid-System. Evidenz zu Sicherheit und Wirksamkeit derzeit limitiert; weitere Forschung erforderlich.
P
PopulationErwachsene mit PTSD
I
InterventionMedizinisches Cannabis und synthetische Cannabinoide
O
OutcomeCannabis und synthetische Cannabinoide zeigen potenziellen therapeutischen Nutzen bei PTSD-Symptomen (Angstreduktion, Gedächtnismodulation, Schlafverbesserung); Evidenzlage jedoch begrenzt
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Background And Objectives: Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating PTSD patients.
Methods: A systematic electronic search was performed, including all papers published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))) for the topics 'Cannabis', 'Synthetic Cannabinoids', 'PTSD', and MESH terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering purposes, PRISMA guidelines were followed. Results were organized into two groups, considering cannabis and synthetic cannabinoids as different therapeutic approaches for
Ptsd. Results: Present data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, modulating memory-related processes, and improving sleep.
Conclusions: Even though the current literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional research is needed in order to better understand the effectiveness and therapeutic usage of these drug classes and monitor their safety.